Boston Scientific (NYSE:BSX) Rating Lowered to "Market Perform" at Oppenheimer

Key Points

• Oppenheimer downgraded Boston Scientific from “outperform” to “market perform,” while the broader analyst consensus remains “Moderate Buy” with a $63.77 target price.
• Boston Scientific’s latest quarter met adjusted EPS expectations at $0.73 and exceeded revenue estimates with $5.14 billion, but revenue growth was modest at 1.4% year over year.
• Cybersecurity disruption and weakening demand pose near-term risks: an eight-day outage reduced quarterly sales by about $150 million, contributing to a lower full-year EPS outlook and expected fourth-quarter sales declines.

Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by analysts at Oppenheimer from an "outperform" rating to a "market perform" rating in a report released on Thursday, MarketBeat reports.

A number of other analysts have also issued reports on BSX. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 2nd. Citigroup lowered their price objective on shares of Boston Scientific from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Monday, October 5th. Mizuho set a $55.00 price objective on shares of Boston Scientific in a research note on Tuesday, October 13th. UBS Group cut their target price on shares of Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, Piper Sandler decreased their target price on shares of Boston Scientific from $65.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Boston Scientific has an average rating of "Moderate Buy" and a consensus target price of $63.77.

Boston Scientific Price Performance

BSX opened at $42.09 on Thursday. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $61.00 billion, a P/E ratio of 17.04, a PEG ratio of 1.10 and a beta of 0.58. The stock has a fifty day moving average of $45.12 and a 200-day moving average of $57.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. During the same period in the prior year, the business earned $0.75 EPS. The business's revenue for the quarter was up 1.4% on a year-over-year basis. Equities analysts forecast that Boston Scientific will post 3.21 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Edward Ludwig bought 5,000 shares of the business's stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 over the last three months. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in the stock. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the 1st quarter worth $28,000. Nvwm LLC lifted its holdings in Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider's stock worth $28,000 after buying an additional 542 shares in the last quarter. Rakuten Securities Inc. bought a new position in Boston Scientific in the 2nd quarter valued at $30,000. Finally, Kings Path Partners LLC bought a new position in Boston Scientific in the 3rd quarter valued at $31,000. Institutional investors own 89.07% of the company's stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue rose 1.5% to $5.138 billion, exceeding analysts’ $5.07 billion estimate, while adjusted EPS of $0.73 matched expectations. Management also reaffirmed its long-term growth strategy and highlighted progress in clinical programs and FDA clearances. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management expects approximately 4% organic revenue growth for full-year 2026 and is targeting a recovery cycle after anticipated 2027 weakness, followed by expansion toward 2030. Recent insider activity also showed purchases rather than sales, including a substantial purchase by CEO Michael Mahoney. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Needham lowered its price target from $57 to $48 but maintained a Buy rating, while JPMorgan downgraded BSX from Overweight to Neutral and set a $46 target. The revised targets remain above the stock’s recent trading level but reflect reduced confidence in the near-term outlook.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to disrupt operations, customer activity, and the recovery timeline. Boston Scientific cut its full-year EPS outlook to $3.16–$3.18 and expects fourth-quarter reported and organic sales to decline 1%–3%. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand, pricing pressure in China, and management’s warning that 2027 could be difficult. GAAP EPS fell to $0.40 from $0.51 a year earlier, and the stock has traded near a four-year low.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.